UMIN-CTR Clinical Trial

UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials


Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000001374
Receipt No. R000001668
Scientific Title Japanese Alzheimer's Disease Neuroimaging Initiative
Date of disclosure of the study information 2008/10/01
Last modified on 2018/03/22

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments

Basic information
Public title Japanese Alzheimer's Disease Neuroimaging Initiative
Acronym J-ADNI
Scientific Title Japanese Alzheimer's Disease Neuroimaging Initiative
Scientific Title:Acronym J-ADNI

Condition Alzheimer's disease, mild cognitive impairment (MCI)
Classification by specialty
Neurology Geriatrics Psychiatry
Classification by malignancy Others
Genomic information YES

Narrative objectives1 To optimize the criteria for evaluation of treatments for Alzheimer's disease (AD), determination of surrogate biomarkers that reflect the pathophysiology of AD is mandatory. J-ADNI study aims at setting the standard values for long-term changes in imaging surrogate markers (e.g., MRI and PET), and simultaneously collecting clinical/neuropsychological data as well as blood/cerebrospinal fluid samples, to eventually prove the adequacy of the surrogate endpoints.
Basic objectives2 Others
Basic objectives -Others Establishment of imaging and biochemical surrogate markers that reflect the progression of Alzheimer's disease.
Trial characteristics_1 Exploratory
Trial characteristics_2
Developmental phase

Primary outcomes Clinical/neuropsychological examinations: CDR, MMSEm WMS-R logical memory I & II, ADAS-Cog, clock drawing/copying, symbol, block design, digit span, knowledge, fluency, trail making test A & B, Boston naming test, geriatric depression scale, Neuropsychiatric Inventory Q, FUnctional activity questionnaire
Magnetic Resonance Imaging of brain: 1.5 tesla MRI in all cases, 3 tesla in 25% of cases
Positron Emission Tomogram: fluorodeoxy glucose PET in 50% of cases
Lumbar puncture: in 50% cases at baseline and 12 months
blood and urine collection in all cases
amyloid PET imaging (25% cases)
Key secondary outcomes

Study type Observational

Study design
Basic design
Randomization unit
Dynamic allocation
Institution consideration

No. of arms
Purpose of intervention
Type of intervention

Age-lower limit
60 years-old <=
Age-upper limit
84 years-old >=
Gender Male and Female
Key inclusion criteria 150 cases of normal aged individuals, 300 cases of MCI, 150 cases of early AD, whose language is Japanese.
Living at home, accompanied by a study partner.
The participants should sign agreement forms. In case the participant is not capable of agreeing, the study partner should sign in substitution.
Age: 60-84 years upon enrollment

Criteria for normal aged individuals
MMSE: 24-30
Scores of Wechsler memory Scale-R logical memory II (corrected for education), above the cut-off levels.
education 0-9 years: 3 or above
10-15 years: 5 or above
>16 years 9 or above

Criteria for amnestic MCI
Type 1: complaint of memory disturbance from the participant plus approval by the study partner
Type 2: memory disturbance approved by the study partner, without the subjective complaint of the participant
(excluded in case only with subjective memory complaint, without approval by the study partner)
MMSE: 24-30
Scores of Wechsler memory Scale-R logical memory II (corrected for education), below the cut-off levels.
education 0-9 years: 2 or lower
10-15 years: 4 or lower
>16 years 8 or lower
CDR 0.5 not depressed

Criteria for early AD
MMSE: 20-26
Scores of Wechsler memory Scale-R logical memory II (corrected for education), below the cut-off levels.
education 0-9 years: 2 or lower
10-15 years: 4 or lower
>16 years 8 or lower
CDR 0.5 or 1
Probable AD by the criteria of NINCDS-ADRDA
(Causes or diseases leading to dementia other than AD excluded)
Key exclusion criteria 1. Parkinson' disease, multiple cerebral infarction, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, epilepsy, subdural hematoma, multiple sclerosis, head trauma with sequelae
2. Signs of brain infection, focal brain lesions (eg infarction) that may affect cognitive function.
3. Presence of pacemaker, arterial clip, artificial valves, artificial cochlea, and other magnetic/electroconductive metals in the body that may affect MRI
4. Major depression or bipolar disorder within past 1 year, addiction to alcohol or other drugs within past 2 years, presence of fatal or unstable diseases, vitamin B12 or folate deficiency, syphilis, thyroid function abnormality
5. administration of psychoactive drugs (defined in procedure manual)
6. administration of warfarin
Target sample size 600

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Takeshi Iwatsubo
Organization School of Medicine, University of Tokyo
Division name Department of Neuropathology
Zip code
Address 7-3-1 Hongo Bunkyoku Tokyo
TEL 03-5841-3541

Public contact
Name of contact person
1st name
Middle name
Last name Kazuya Omura
Organization administration office of J-ADNI
Division name office of clinical study administration
Zip code
Address 4-1-1 Ogawahigashimachi Kodaira
TEL 042-347-3326
Homepage URL

Institute J-ADNI study group

Funding Source
Organization NEDO translational research funding
Category of Funding Organization Japanese Governmental office
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor Research association for Biotechnology
Name of secondary funder(s) Ministry of Health, Labor and Welfare

IRB Contact (For public release)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2


Other administrative information
Date of disclosure of the study information
2008 Year 10 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

URL related to results and publications
Number of participants that the trial has enrolled
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Recruitment status No longer recruiting
Date of protocol fixation
2008 Year 05 Month 07 Day
Date of IRB
Anticipated trial start date
2008 Year 09 Month 01 Day
Last follow-up date
2015 Year 09 Month 01 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other related information Clinical/neuropsychological evaluation, neuroimaging work-ups and collection of biofluid samples are undertaken longitudinally at baseline, 6,12,24,36 M (normal individuals), baseline, 6,12,18,24,36M (MCI) and baseline, 6, 12, 24 M (early AD).

Management information
Registered date
2008 Year 09 Month 13 Day
Last modified on
2018 Year 03 Month 22 Day

Link to view the page

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name

Contact us.